Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

Ashton, Nicholas J.Puig-Pijoan, AlbertMilà-Alomà, MartaFernández-Lebrero, AidaGarcía-Escobar, GretaGonzález-Ortiz, FernándoKac, Przemysław R.Brum, Wagner S.Benedet, Andréa L.Lantero-Rodriguez, JuanDay, Theresa A.Vanbrabant, JeroenStoops, ErikVanmechelen, EugeenTriana-Baltzer, GallenMoughadam, SetarehKolb, HartmuthOrtiz-Romero, PaulaKarikari, Thomas K.Minguillon, CarolinaHernández Sánchez, Juan JoséNavalpotro-Gómez, IreneGrau-Rivera, OriolManero, Rosa MaríaPuente-Periz, Víctorde la Torre, RafaelRoquer, JaumeDage, Jeff L.Zetterberg, HenrikBlennow, KajSuárez-Calvet, Marc2024-08-032024-08-032023Ashton NJ, Puig-Pijoan A, Milà-Alomà M, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19(5):1913-1924. doi:10.1002/alz.12841https://hdl.handle.net/1805/42588Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio. Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts.en-USPublisher PolicyBiomarkerDementiaDiseasePhosphorylated tauPlasmaTauPlasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassaysArticle